Previous 10 | Next 10 |
2024-05-19 08:02:00 ET Retailers will also be in the spotlight, with updates anticipated from Target ( NYSE: TGT ), Lowe's ( LOW ), Macy’s ( M ), Ross Stores ( ROST ), TJX Companies ( TJX ), Ralph Lauren ( RL ) and Urban Outfitters ( URBN ).... R...
2024-05-17 13:38:19 ET More on Compugen Compugen Ltd. (CGEN) Q4 2023 Earnings Call Transcript Compugen names David Silberman as finance chief Compugen GAAP EPS of $0.11 beats by $0.01, revenue of $33.46M beats by $13.46M Seeking Alpha’s Quant Rating on...
Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential PR Newswire HOLON, Israel , May 16, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pion...
2024-05-15 07:43:21 ET More on Compugen Compugen Ltd. (CGEN) Q4 2023 Earnings Call Transcript Compugen GAAP EPS of $0.11 beats by $0.01, revenue of $33.46M beats by $13.46M Seeking Alpha’s Quant Rating on Compugen Historical earnings data for Compugen ...
Compugen Appoints David Silberman as Chief Financial Officer PR Newswire HOLON, Israel , May 15, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, toda...
2024-05-13 07:58:54 ET Merck ( NYSE: MRK ) has discontinued the vibostolimab and pembrolizumab coformulation arm of a late-stage skin cancer trial .... Read the full article on Seeking Alpha For further details see: Merck discontinues testing of experimental skin...
Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024 PR Newswire HOLON, ISRAEL , May 6, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discov...
Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024 PR Newswire HOLON, Israel , April 25, 2024 /PRNewswire/ -- Compugen Ltd...
Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503 PR Newswire HOLON, Israel , April 10, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pione...
Compugen to Participate in Two Upcoming Investor Conferences PR Newswire HOLON, Israel , April 3, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, tod...
News, Short Squeeze, Breakout and More Instantly...
Compugen to Present at Upcoming Antibody Industrial Symposium PR Newswire HOLON, Israel , June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, t...
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig PR Newswire Phase 3 trial evaluating rilvegostomig as monotherapy and in combination with AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan in ...
A look at the top 10 most actives in the United States Greenwave Technology Solutions Inc. (GWAV) rose 33.8% to $0.0788 on volume of 1,221,538,672 shares Akoustis Technologies Inc. (AKTS) rose 128.8% to $0.3151 on volume of 536,119,838 shares Crown Electrokinetics Corp. (CRKN) rose 3.1% t...